Drugs / LabVax 3(22)-23
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05101356 | Jan 2021 → Dec 2030 | adenocarcinoma, metastatic malignant neoplasm | University of California, Davis | Suspended | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07859592 | Dec 2026 → Nov 2030 expected | adenocarcinoma, chemotherapy-induced toxicity | VA Office of Research and Development | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LabVax 3(22)-23 | “Patients receive sargramostim SC and LabVax 3(22)-23 ID on weeks 1, 2, 4, 8, and 12 in the absence of disease progression or unacceptable toxicity.” NCT05101356 ↗ |
| Modality | Vaccine | “This phase 1/2 trial tests the safety and effectiveness of a cancer vaccine called Labvax 3(22)-23 and GM-CSF alone or in combination with pembrolizumab” NCT05101356 ↗ |